{"id":11697,"date":"2021-02-02T16:16:19","date_gmt":"2021-02-02T10:46:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11697"},"modified":"2021-07-24T12:58:15","modified_gmt":"2021-07-24T07:28:15","slug":"pharma-happenings-for-gilead-arcus-gritstone-viela-horizon","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-arcus-gritstone-viela-horizon","title":{"rendered":"Horizon, Viela Deal; Concert  Schizo Drug Flop; Gilead Deals with Arcus and Gritstone"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fea8efdb887\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fea8efdb887\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-arcus-gritstone-viela-horizon\/#Horizon_Therapeutics_Bolsters_its_Rare_Disease_Portfolio_in_a_3B_Viela_Bio_Buyout\" >Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio Buyout<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-arcus-gritstone-viela-horizon\/#Concert_Pharmaceuticals_Falls_Flat_After_its_Schizophrenia_Drug_Fails\" >Concert Pharmaceuticals Falls Flat After its Schizophrenia Drug Fails<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-arcus-gritstone-viela-horizon\/#Gilead_fronts_220M_for_Arcus_in_exchange_for_a_larger_ownership_stake\" >Gilead fronts $220M for Arcus in exchange for a larger ownership stake<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-arcus-gritstone-viela-horizon\/#Gilead_and_Gritstone_on_Their_Way_to_Find_HIV_Cure_Through_a_USD_785_Million_Deal\" >Gilead and Gritstone on Their Way to Find HIV Cure Through a USD 785 Million Deal&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Horizon_Therapeutics_Bolsters_its_Rare_Disease_Portfolio_in_a_3B_Viela_Bio_Buyout\"><\/span><strong>Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio Buyout<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Horizon Therapeutics has announced to acquire Viela Bio for about $3.1 billion to augment its portfolio and pipeline of treatments for rare diseases. The shares of Viela Bio skyrocketed more than 52% in premarket trading after the news was broadcasted.&nbsp; The deal is expected to close by the end of the first quarter.<\/p>\n\n\n\n<p>Viela Bio proved its worth in the pharmaceutical industry after winning the approval for its&nbsp; <strong>Uplizna<\/strong>, a drug that received FDA approval for Neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition. It is the only approved drug available in the NMOSD market. Thus, the news of its acquisition does not surprise as a horde of pharma giants would be keeping a keen eye on its activities.&nbsp;<\/p>\n\n\n\n<p>The Viela Bio acquisition will add four therapeutic candidates currently in nine development programs to the Horizon\u2019s portfolio. The current Viela pipeline includes four therapeutic candidates currently in nine development programs. Besides Uplizna, VIB4920, VIB7734 and VIB1116 are the three candidates in different stages of clinical development. While <strong>VIB4920 <\/strong>is under evaluation in Phase IIb trial in <a href=\"https:\/\/www.delveinsight.com\/report-store\/sjogrens-syndrome-market-size?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">Sj\u00f6gren\u2019s syndrome<\/a> and Phase II trials for kidney transplant rejection and rheumatoid arthritis; <strong>VIB7734 <\/strong>is undergoing Phase II for <a href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-lupus-erythematosus-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">systemic lupus erythematosus<\/a> and Phase I for treatment of COVID-19-related acute lung injury. The remaining <strong>VIB1116<\/strong> is still in preclinical stages expected to enter the clinic later this year.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Concert_Pharmaceuticals_Falls_Flat_After_its_Schizophrenia_Drug_Fails\"><\/span><strong>Concert Pharmaceuticals Falls Flat After its Schizophrenia Drug Fails<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Concert Pharmaceuticals stocks took a considerable fall after the news of a major flop of its Phase II clinical trial for its adjunctive <a href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">schizophrenia<\/a> treatment,<strong> CTP-692 <\/strong>broke out. The trial failed to meet primary endpoint or other secondary endpoints.\u00a0<\/p>\n\n\n\n<p>CTP-692 is a deuterated form of D-serine, which is an endogenous amino acid. It also acts as a co-agonist of the NMDA receptor. The adjunctive candidate was developed with an aim to improve renal safety and brain exposure related to the amino acid. It was one of the two candidates in the clinical development, however, the company with a heavy heart has decided to shelve its development plans.<\/p>\n\n\n\n<p>Concert now plans to focus on its remaining candidate <strong>CTP-543<\/strong>, which is in Phase III THRIVE-AA1 clinical trial to evaluate this treatment therapy in patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/alopecia-areata-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">alopecia areata<\/a>, an autoimmune disease that causes hair loss. Now that the chips are down, the only hope for the company is its hair-loss candidate. However, there are other potential candidates in the company\u2019s armamentarium that are in the pre-clinical setting and if everything goes as planned, can advance further.\u00a0\u00a0<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gilead_fronts_220M_for_Arcus_in_exchange_for_a_larger_ownership_stake\"><\/span><strong>Gilead fronts $220M for Arcus in exchange for a larger ownership stake<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Gilead has willed itself to increase its stake in Arcus Biosciences by infusing a sum of roughly USD 220 million. Gilead\u2019s ownership in Arcus will increase to 19.5%, from approximately 13%, with the purchase of 5,650,000 additional Arcus shares at a price of $39 per share.<\/p>\n\n\n\n<p>The proceeds from the funding will help Arcus to fund its operations through at least 2023. The company plans to carry forward the development plans of four clinical-stage molecules, including AB680, a small molecule CD73 inhibitor, for first-line <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-pancreatic-cancer-mpc-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">metastatic pancreatic cancer<\/a><\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gilead_and_Gritstone_on_Their_Way_to_Find_HIV_Cure_Through_a_USD_785_Million_Deal\"><\/span><strong>Gilead and Gritstone on Their Way to Find HIV Cure Through a USD 785 Million Deal&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Looks like the pharma titan, Gilead is on a collaboration spree with different pharma companies, sometimes by making heavy deals and other times by acquiring a larger stake in them.&nbsp;<\/p>\n\n\n\n<p>Gilead has announced a collaboration with <strong>Gritstone Oncology <\/strong>to work on a cure for HIV. The companies are going to develop vaccine-based immunotherapy as a <a href=\"https:\/\/www.delveinsight.com\/blog\/curing-hiv-with-gene-therapy\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">cure for HIV<\/a>. What draws the attention here is the commitment of the companies to find a standard cure for the disease. At present, the disease is treated with a combination of options managed and controlled with cocktails of antiviral drugs, however, the actual cure remains elusive.<\/p>\n\n\n\n<p>Gilead holds a strong profile in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/autoimmune-hepatitis-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">Hepatitis<\/a> and HIV treatment market. The partnership will profoundly help in exploiting Gritstone\u2019s technology platforms namely <strong>Gritstone EDGE<\/strong> that predicts antigens presented on the surface of cells, such as cancer cells or cells infected by viruses, and the other that can be leveraged to develop and manufacture potent immunotherapies using those antigens.<\/p>\n\n\n\n<p>The total deal sums over USD 785 million, with $30 million in cash up front and a $30 million equity investment. Gritstone will also be eligible for an additional $725 million in regulatory and commercial milestones, as well as mid-single-digit to low double-digit tiered royalties on net sales.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio Buyout Horizon Therapeutics has announced to acquire Viela Bio for about $3.1 billion to augment its portfolio and pipeline of treatments for rare diseases. The shares of Viela Bio skyrocketed more than 52% in premarket trading after the news was broadcasted.&nbsp; The deal [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":11700,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[16873,16659,268,297,2424,6818,16874,1519,721],"industry":[17225],"therapeutic_areas":[17237,17239,17227,17231,17228],"class_list":["post-11697","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alopecia-areata","tag-covid","tag-gilead-biosciences","tag-hiv","tag-immunotherapies","tag-metastatic-pancreatic-cancer-market","tag-neuromyelitis-optica-spectrum-disorder","tag-schizophrenia","tag-systemic-lupus-erythematosus","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-gastroenterology","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead, Gritstone Deal<\/title>\n<meta name=\"description\" content=\"Horizon Nabs Viela Bio, Concert&#039;s Schizophrenia Drug Fails; Gilead Ups its Arcus Stake; Gilead, Gritstone $785M Deal for HIV Cure\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-arcus-gritstone-viela-horizon\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead, Gritstone Deal\" \/>\n<meta property=\"og:description\" content=\"Horizon Nabs Viela Bio, Concert&#039;s Schizophrenia Drug Fails; Gilead Ups its Arcus Stake; Gilead, Gritstone $785M Deal for HIV Cure\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-arcus-gritstone-viela-horizon\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-02T10:46:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/02160522\/Horizon-Viela-Deal-Concert-Schizo-Drug-Flop-Gilead-Gritstone-Deal.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead, Gritstone Deal","description":"Horizon Nabs Viela Bio, Concert's Schizophrenia Drug Fails; Gilead Ups its Arcus Stake; Gilead, Gritstone $785M Deal for HIV Cure","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-arcus-gritstone-viela-horizon","og_locale":"en_US","og_type":"article","og_title":"Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead, Gritstone Deal","og_description":"Horizon Nabs Viela Bio, Concert's Schizophrenia Drug Fails; Gilead Ups its Arcus Stake; Gilead, Gritstone $785M Deal for HIV Cure","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-arcus-gritstone-viela-horizon","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-02-02T10:46:19+00:00","article_modified_time":"2021-07-24T07:28:15+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/02160522\/Horizon-Viela-Deal-Concert-Schizo-Drug-Flop-Gilead-Gritstone-Deal.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-arcus-gritstone-viela-horizon","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-arcus-gritstone-viela-horizon","name":"Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead, Gritstone Deal","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-arcus-gritstone-viela-horizon#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-arcus-gritstone-viela-horizon#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/02160522\/Horizon-Viela-Deal-Concert-Schizo-Drug-Flop-Gilead-Gritstone-Deal.jpg","datePublished":"2021-02-02T10:46:19+00:00","dateModified":"2021-07-24T07:28:15+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Horizon Nabs Viela Bio, Concert's Schizophrenia Drug Fails; Gilead Ups its Arcus Stake; Gilead, Gritstone $785M Deal for HIV Cure","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-arcus-gritstone-viela-horizon"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-arcus-gritstone-viela-horizon#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/02160522\/Horizon-Viela-Deal-Concert-Schizo-Drug-Flop-Gilead-Gritstone-Deal.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/02160522\/Horizon-Viela-Deal-Concert-Schizo-Drug-Flop-Gilead-Gritstone-Deal.jpg","width":772,"height":482,"caption":"Horizon, Viela Deal; Concert Schizophrenia Drug Flop; Gilead, Gritstone Deal"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/02160522\/Horizon-Viela-Deal-Concert-Schizo-Drug-Flop-Gilead-Gritstone-Deal-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">alopecia areata<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gilead Biosciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HIV<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">immunotherapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">metastatic pancreatic cancer market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neuromyelitis optica spectrum disorder<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">schizophrenia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">alopecia areata<\/span>","<span class=\"advgb-post-tax-term\">COVID<\/span>","<span class=\"advgb-post-tax-term\">Gilead Biosciences<\/span>","<span class=\"advgb-post-tax-term\">HIV<\/span>","<span class=\"advgb-post-tax-term\">immunotherapies<\/span>","<span class=\"advgb-post-tax-term\">metastatic pancreatic cancer market<\/span>","<span class=\"advgb-post-tax-term\">Neuromyelitis optica spectrum disorder<\/span>","<span class=\"advgb-post-tax-term\">schizophrenia<\/span>","<span class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Feb 2, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Feb 2, 2021 4:16 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"Horizon, Viela Deal; Concert Schizophrenia Drug Flop; Gilead, Gritstone Deal","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11697"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11697\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11700"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11697"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11697"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11697"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11697"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}